The COVID-19 molecular test kit produced and manufactured in Peru —named CavBio— was authorized by the
General Directorate for Medicines, Supplies, and Drugs (Digemid) of the Ministry of Health to enter the national market and, thus, contribute to the fight against the second wave of the novel coronavirus.
The kit consists of six reagents based on RT-PCR methodology, which detect the SARS-CoV-2 virus in a swab sample. The test can diagnose COVID-19, including the variants found in the United Kingdom, South Africa, and Brazil.
"We have technically demonstrated that the variants can be detected. It (the test kit) does not make difference among them, but it does confirm the detection of the virus," BTS Consultores Research Director Milagros Zavaleta stated.
The manufacture and use of this kit was authorized by Board Resolution No. 605-2021 within the framework of the state of emergency decreed to contain the spread of the COVID-19 pandemic.
Thus, the health authority issued a temporary registration for the kit to enter the national market.
Each box will contain 100 tests —where reagents will be stored in nuclease-free polypropylene tubes— as well as a manual.
According to Zavaleta, talks are being held with laboratories and clinics for the sale of the first kits.
It must be noted that the company is capable of producing one million kits per month.
(END) SPV/RMB
Publicado: 25/1/2021